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Rho is a presynaptic activator of
neurotransmitter release at pre-existing
synapses in C. elegans
Rachel McMullan, Emma Hiley, Paul Morrison, and Stephen J. Nurrish1
MRC Cell Biology Unit, MRC Laboratory for Molecular Cell Biology and Department of Pharmacology, University College,
London WC1E 6BT, United Kingdom
Rho GTPases have important roles in neuronal development, but their function in adult neurons is less well
understood. We demonstrate that presynaptic changes in Rho activity at Caenorhabditis elegans
neuromuscular junctions can radically change animal behavior via modulation of two separate pathways. In
one, presynaptic Rho increases acetylcholine (ACh) release by stimulating the accumulation of diacylglycerol
(DAG) and the DAG-binding protein UNC-13 at sites of neurotransmitter release; this pathway requires
binding of Rho to the DAG kinase DGK-1. A second DGK-1-independent mechanism is revealed by the ability
of a Rho inhibitor (C3 transferase) to decrease levels of release even in the absence of DGK-1; this pathway is
independent of UNC-13 accumulation at release sites. We do not detect any Rho-induced changes in neuronal
morphology or synapse number; thus, Rho facilitates synaptic transmission by a novel mechanism.
Surprisingly, many commonly available human RhoA constructs contain an uncharacterized mutation that
severely reduces binding of RhoA to DAG kinase. Thus, a role for RhoA in controlling DAG levels is likely to
have been underestimated.
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Extracellular neuromodulators can alter levels of neuro-
transmitter release at many, if not all, synapses (for re-
views, see Miller 1998; Ghijsen and Miriam Leenders
2005). Although many of the molecular components that
underlie neurotransmitter release have been characterized
(for review, see Sudhof 2004), less is known about how
they are regulated by the intracellular signaling path-
ways that modulate levels of neurotransmitter release.
Rho GTPases are a family of small GTP-binding pro-
teins that regulate a wide variety of signal transduction
pathways in all eukaryotic cells (Etienne-Manneville and
Hall 2002). The three best studied members of the fam-
ily—Rho, Rac, and Cdc42—have important roles in the
developing nervous system (Govek et al. 2005) and in the
regulation of synaptic function, as revealed by behavioral
studies. Gene knockouts of several Rho GTPase effectors
(PAK, WAVE-1, or LIMK-1) impair learning and memory
in mice (Meng et al. 2002, 2004; Soderling et al. 2003),
while inhibition of the Rho effector p160ROCK impairs
long-term memory in rats (Dash et al. 2004). In humans,
defects in genes for regulators (ARHGEF6, OPHN1) or
effectors (LIMK-1, PAK3) of Rho GTPases are associated
with mental retardation (Ramakers 2002; Chechlacz and
Gleeson 2003).
One possible role for Rho GTPases at synapses is to
regulate levels of neurotransmitter release by modulat-
ing synaptic vesicle exocytosis. Rac and Cdc42 have
been shown to regulate synaptic strength by acting pre-
synaptically in Aplysia (Humeau et al. 2002; Udo et al.
2005), and to induce exocytosis in mammalian secretory
cells (Kowluru et al. 1997; Brown et al. 1998). A role for
Rho in the regulation of neurotransmitter release is,
however, less clear. Potentiation of acetylcholine (ACh)
release by lysophosphatidic acid in PC12 cells requires
RhoB (Ishida et al. 2004), but, in contrast, adrenalin re-
lease from permeabilized PC12 cells has been reported to
be independent of RhoA (Wang et al. 2004).
To investigate the role of Rho in regulating neuro-
transmitter release, we have examined the effect of Rho-
influencing transgenes on ACh release at the Cae-
norhabditis elegans neuromuscular junction. The single
C. elegans Rho ortholog (RHO-1) is expressed through-
out the nervous system (Chen and Lim 1994) and is re-
quired for normal cell migration, cell shape regulation,
and neurite outgrowth (Zallen et al. 2000; Spencer et al.
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2001; Dalpe et al. 2004). We report here that RHO-1 can
enhance ACh release by at least two mechanisms—one
dependent on the diacylglycerol (DAG) kinase DGK-1
and one DGK-1-independent. We also show that RHO-1
stimulates synaptic signaling by increasing muscle sen-
sitivity to ACh. Thus, RHO-1 can use three distinct
pathways to strengthen synaptic signaling at the C. el-
egans neuromuscular junction.
Results
RHO-1 regulates neurotransmitter release
at neuromuscular junctions
We used the Clostridium botulinum-derived C3 trans-
ferase to inhibit the function of RHO-1 in C. elegans. C3
transferase ADP-ribosylates and inactivates Rho without
affecting other Rho family proteins, including Rac and
Cdc42 (Aktories and Hall 1989). Expression of N-termi-
nally GFP-tagged C3 transferase from an inducible heat-
shock promoter in adult C. elegans resulted in a major
change in behavior, greatly decreasing animal movement
as measured by a decrease in body bends per minute and
very shallow body bends (Fig. 1A,B). To test whether
RHO-1 acts pre- or post-synaptically, we expressed C3
transferase in ACh-releasing neurons, using the pro-
moter for the unc-17 gene, which encodes the ACh trans-
porter in synaptic vesicles (Alfonso et al. 1993). These
animals also displayed decreased movement compared
with wild-type animals (Fig. 1A,B), confirming that in-
hibition of endogenous RHO-1 signaling in ACh-releas-
ing cells changes C. elegans locomotion.
To further test the role of RHO-1 in neurotransmitter
release, we expressed a constitutively active RHO-
1(G14V) mutant from either an inducible heat-shock
promoter or the unc-17 promoter. In both cases, expres-
sion of RHO-1(G14V) also changed adult behavior, but in
this case movement was greatly increased, as measured
Figure 1. RHO-1 signaling alters animal behavior
and acetylcholine release. Mutant behavioral as-
says and transgenic animals were as described in
Materials and Methods. (A) Inhibition of endog-
enous RHO-1 by expression of C3 transferase from
heat-shock (hs:) or neuronal (N:) (using the unc-17
promoter) promoters decreased locomotion,
whereas expression of a constitutively active RHO-
1(G14V) mutant from heat-shock or neuronal pro-
moters increased locomotion. Statistical analysis
was performed using a two-tailed t-test, and signifi-
cance is indicated with two asterisks (**, p < 0.001).
(B) Locomotion phenotypes of the mutants de-
scribed in this study. Inhibition of endogenous
RHO-1 by heat-shock (hs:C3T) or presynaptic (from
the unc-17 promoter, N:C3T) expression of C3
transferase causes flattened sinusoidal tracks com-
pared with wild type. Heat-shock [hs:RHO-
1(G14V)] and presynaptic [N:RHO-1(G14V)] expres-
sion of RHO-1(G14V) results in exaggerated sinu-
soidal tracks compared with wild type. (C–E)
Synaptic release of endogenous acetylcholine (ACh)
was measured by determining the onset of paralysis
induced by the acetylcholinesterase inhibitor aldi-
carb. Expression of C3 transferase from either heat-
shock (hs:C3 transferase + hs) (C) or the presynaptic
unc-17 (N:C3T) (D) promoter delayed the onset of
paralysis of animals treated with aldicarb relative
to non-heat-shocked animals (hs:C3 transferase −
hs) or wild-type animals (wt), suggesting a decrease
in levels of ACh release. In contrast, expression of
the constitutively active RHO-1(G14V) from either
heat-shock [RHO-1(G14V) + hs] (E) or unc-17
(N:C3T) (D) promoters results in a faster onset of
paralysis relative to non-heat-shocked animals
[RHO-1(G14V) − hs] or wild-type (wt) animals, sug-
gesting that the normal role of RHO-1 activation is
to increase ACh release. Error bars indicate stan-
dard error of the mean.
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by an increase in body bends per minute, and animals
produced exaggerated body bends with increased bend
amplitude, producing loopy locomotion (Fig. 1A,B).
To relate the behavioral effects of changing RHO-1
activity to ACh levels, we quantified the responsiveness
of animals to the acetylcholinesterase inhibitor aldicarb.
Aldicarb prevents the removal of endogenously released
ACh, which allows ACh to build up to a level sufficient
to hypercontract the body wall muscles and cause pa-
ralysis in wild-type animals, but not in mutants that are
defective in ACh release (Nonet et al. 1993; Nguyen et
al. 1995; Miller et al. 1996). In the presence of aldicarb,
heat-shock-induced expression of C3 transferase in adult
animals strongly reduced the extent of paralysis com-
pared with both noninduced animals and wild-type ani-
mals (Fig. 1C). Presynaptic expression of C3 transferase
from the unc-17 promoter also increased resistance to
aldicarb treatment compared with wild-type animals
(Fig. 1D). In contrast, heat-shock expression of the con-
stitutively active RHO-1(G14V) mutant in adult animals
resulted in hypersensitivity to aldicarb (Fig. 1E). RHO-
1(G14V) acted presynaptically, as animals expressing ac-
tivated RHO-1(G14V) in motor neurons from the unc-17
promoter also became paralyzed faster with aldicarb
treatment compared with wild-type animals (Fig. 1D).
Taken together, these results suggest that activation of
RHO-1 enhances ACh release, leading to changes in be-
havior.
RHO-1 enhances ACh release at pre-existing synapses
In principle, RHO-1 could increase ACh release either by
increasing ACh release at existing synapses, by stimu-
lating the formation of new ACh-releasing synapses, or
both. We tested the possibility that RHO-1 increased the
formation of new synapses in two ways. First, we looked
for changes in neuronal connectivity by assessing GFP-
labeled motor neurons and found no obvious morpho-
logical differences in wild-type, C3 transferase, and
RHO-1(G14V)-expressing motor neurons (Supplemen-
tary Fig. 1). Second, we expressed CFP-labeled synapto-
brevin (SNB-1CFP), an integral membrane protein en-
riched in synaptic vesicles, in the ACh-releasing motor
neurons to measure the number of release sites before
and after heat-shock-induced expression of the constitu-
tively active RHO-1(G14V). After heat-shock induction
of RHO-1(G14V), we saw no change in the number of
SNB-1CFP puncta compared with noninduced animals
(3.2 ± 0.4 vs. 2.9 ± 0.2 puncta per 10 µm; mean ± SEM;
Supplementary Fig. 2). Similarly, expression of RHO-
1(G14V) in ACh-releasing neurons (from the unc-17 pro-
moter) did not alter the number of SNB-1CFP puncta
when compared with wild-type controls (3.2 ± 0.2 vs.
3.4 ± 0.1 puncta per 10 µm; mean ± SEM; Supplementary
Fig. 2). We conclude that RHO-1(G14V) exerts its effects
by increasing ACh release at pre-existing synapses and
not by increasing the number of synapses. C3 transferase
was tagged with GFP, and we were unable to visualize
SNB-1CFP puncta; thus, it is possible that inhibition of
endogenous RHO-1 may cause a decrease in numbers of
release sites.
RHO-1 interacts with DGK-1
How does RHO-1 enhance neurotransmitter release?
Mammalian RhoA has been shown to bind and inhibit
the DAG kinase DGK (Houssa et al. 1999; Los et al.
2004). DAG kinases remove the membrane-bound sec-
ond messenger DAG, which enhances neurotransmitter
release in both mice and C. elegans (Lackner et al. 1999;
Miller et al. 1999; Brose and Rosenmund 2002; Silinsky
and Searl 2003; Brose et al. 2004), and the C. elegans
ortholog of DGK, DGK-1, acts in motor neurons to in-
hibit ACh release (Nurrish et al. 1999). Interestingly, ani-
mals expressing constitutively active RHO-1(G14V) be-
have very similarly to both animals exposed to the DAG
analog phorbol ester and animals lacking DGK-1 (Hajdu-
Cronin et al. 1999; Lackner et al. 1999; Miller et al. 1999;
Nurrish et al. 1999), whereas animals overexpressing
DGK-1 resemble animals expressing C3 transferase.
Thus, DGK-1 is a possible target of negative regulation
by RHO-1. To test if the interaction between RHO-1 and
DGK-1 is conserved in C. elegans, we expressed HA-
tagged, full-length DGK-1, together with myc-tagged, ac-
tive RHO-1(G14V), in Cos7 cells. DGK-1 does coimmu-
noprecipitate with constitutively active RHO-1(G14V)
(Fig. 2A), confirming that the interaction is conserved
between mammals and nematodes. As a control, we also
expressed human VSV-tagged DGK, along with myc-
tagged constitutively active RhoA(G14V), and showed
that they coimmunoprecipitated (Fig. 2A).
To identify the region of DGK-1 required for coimmu-
noprecipitation with RHO-1, we expressed various dele-
tions of DGK-1 (data not shown). We found that the last
247 amino acids of DGK-1 were sufficient for binding to
constitutively active RHO-1(G14V) and, at a lower level,
to wild-type RHO-1 (Fig. 2B). This DGK-1 fragment con-
tains the DGK accessory domain, which is C-terminal to
the DGK catalytic domain in all DAG kinases (Sakane
and Kanoh 1997). The equivalent C-terminal fragment of
human DGK was also able to interact with constitu-
tively active human RhoA(G14V) with a higher affinity
than with wild-type RhoA, and this interaction was par-
tially blocked by expression of C3 transferase (Fig. 2C).
In our initial studies, we discovered that RhoA con-
structs from three different sources contained an addi-
tional undocumented mutation (F25N). This mutation
significantly reduced the interaction between constitu-
tively active RHO-1(G14V) and DGK-1 (Fig. 2B). Binding
of the human RhoA (G14VF25N) to DGK was also sig-
nificantly reduced by this amino acid substitution (Fig.
2C). We tested the effect of the F25N mutation on the
ability of human myc-tagged RhoA(G14V) expressed in
Cos7 cells to bind other effectors. The F25N mutation
did not alter the ability of constitutively active
RhoA(G14V) to bind GST fusions of other Rho effectors:
PKN(1–511), mDia(47–257), and ROCKII(348–1018) (Fig.
2D). Thus, the F25N mutation selectively reduces Rho
binding to DGK, rather than all effectors.
Rho enhances neurotransmitter release
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The strength of RHO-1(G14V) binding to DGK-1
correlates with the potentiation of ACh release
To assess the effect of reduced RHO-1 binding to DGK-1
on neurotransmitter release, we expressed RHO-
1(G14VF25N) presynaptically using the unc-17 pro-
moter. Presynaptic expression of the poor DGK-1-bind-
ing RHO-1(G14VF25N) caused loopy locomotion, but
the rate of locomotion, while higher than in wild-type
animals, was slower than in animals with neuronal ex-
pression of constitutively active RHO-1(G14V), which
binds more strongly to DGK-1 (Fig. 3A). In addition, pre-
synaptic expression of RHO-1(G14VF25N) resulted in
animals with an intermediate response to aldicarb treat-
ment, between the response of animals expressing RHO-
1(G14V), which retains full binding to DGK-1, and wild-
type (Fig. 3B). If RHO-1(G14VF25N) is defective only be-
cause of its inability to bind and inhibit DGK-1, then
removal of DGK-1 should compensate for the F25N mu-
tation. This was the case: The locomotion and aldicarb
sensitivity of dgk-1-null animals expressing the RHO-
1(G14VF25N) mutant that bound DGK-1 poorly was in-
distinguishable from animals expressing RHO-1(G14V)
(Fig. 3A,B). If RHO-1 acts through inhibition of DGK-1,
then we would predict that dgk-1 mutations should not
enhance the locomotion of animals expressing RHO-
1(G14V). Animals expressing RHO-1(G14V) but lacking
DGK-1 did not show significantly increased locomotion
rates when compared with RHO-1(G14V) in a wild-type
background (Fig. 3A), which suggests that RHO-1 and
DGK-1 act in the same pathway.
RHO-1 also stimulates ACh release through
a DGK-1-independent pathway
If RHO-1 stimulates ACh release exclusively by inhibit-
ing DGK-1, then the removal of DGK-1, using a dgk-1-
null mutant, should completely suppress the effects of
lowering endogenous RHO-1 signaling. The reduced lo-
comotion and ACh release effects of C3 transferase ex-
pressed from the unc-17 promoter were suppressed in a
dgk-1-null mutant (Fig. 4A,B), but not completely. Thus,
even in the complete absence of DGK-1, the inhibition of
endogenous RHO-1 activity by C3 transferase is still ca-
pable of reducing locomotion and ACh release. This sug-
gests that RHO-1 activates two presynaptic pathways,
one DGK-1-dependent and one DGK-1-independent, in
stimulating C. elegans locomotion.
Figure 2. DGK-1 interacts with RHO-1. (A) Both
full-length human DGK (VSV-tagged) and constitu-
tively active RhoA(G14V) (myc-tagged) (left panels)
or their C. elegans orthologs DGK-1 (HA-tagged) and
RHO-1(G14V) (myc-tagged) (right panels) coimmu-
noprecipitated when coexpressed in Cos7 cells. Cells
were lysed and RHO-1 immunoprecipitated with the
anti-myc monoclonal antibody 9E10. (Upper panel)
Coimmunoprecipitated DGK or DGK-1 was visual-
ized by Western blotting. Lower panels show expres-
sion controls (total lysates). The ratio of coimmuno-
precipitated DGK (IP) to total DGK (VSVtotal) was
determined by densitometry and is indicated below
each lane. (B) Cos7 cells were cotransfected with
truncated DGK-1 (HA-DGK-1acc) and wild-type,
G14V, or G14VF25N RHO-1 (myc-tagged). DGK-1
acc (lane 1) coimmunoprecipitated with RHO-
1(G14V) with higher affinity than wild-type RHO-1
(lane 2), but this interaction was strongly reduced
with the RHO-1(G14VF25N) mutant (lane 3). Lanes
4–6 show single-transfection controls. The ratio of
coimmunoprecipitated DGK-1(IP) to total DGK-
1(HAtotal) was determined by densitometry and is
indicated below each lane. (C) Cos7 cells were co-
transfected with truncated human DGK (VSV
DGK acc), together with either wild-type, G14V or
G14VF25N RhoA (myc-tagged), and C3 transferase.
DGK acc coimmunoprecipitated with RhoA(G14V)
(lane 1) with a higher affinity than wild-type RhoA
(lane 2) or RhoA(G14VF25N) (lane 4). (Lane 3) Coex-
pression of C3 transferase partially decreased binding
of wild-type RhoA to truncated DGK. Lanes 5–6
show single-transfection controls. The ratio of coimmunoprecipitated DGK (IP) to total DGK (VSVtotal) was determined by den-
sitometry and is indicated below each lane. (D) G14V or G14VF25N RhoA (myc-tagged) were transfected into Cos7 cells. Cells were
lysed, and lysates were incubated with GST fusions of PKN, mDia, or ROCKII. Following washing, bound RhoA was detected by
Western blotting and quantified using densitometry. The data represent the mean of three separate experiments; error bars indicate the
standard error of the mean. The additional F25N mutation does not block the binding of RhoA(G14V) to PKN, mDia, or ROCKII. No
significant differences were detected between G14V and G14VF25N RhoA using a two-tailed t-test (p > 0.02).
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RHO-1 increases the abundance of UNC-13 at sites
of ACh release
We have previously shown that DGK-1 acts within the
motor neurons to inhibit ACh release by removal of
DAG (Nurrish et al. 1999). DAG increases ACh release
in the motor neurons by the recruitment of the DAG-
binding protein UNC-13 to neurotransmitter release
sites (Lackner et al. 1999; Nurrish et al. 1999). Thus, we
expected that RHO-1-mediated inactivation of DGK-1
would increase DAG levels and alter UNC-13 localiza-
tion. Consistent with this, expression of constitutively
activated RHO-1(G14V) from the heat-shock promoter
caused an increase in the number of UNC-13SYFP
punctate structures in the dorsal nerve cord, where neu-
romuscular junctions are located (Fig. 5A–D,G). To
confirm that the relocalization of UNC-13 was due
to changes in DAG levels, we expressed a mutant form
of UNC-13, H173K, which is unable to bind to DAG
(Kazanietz et al. 1995; Zhang et al. 1995; Betz et al. 1998).
The non-DAG-binding UNC-13S(H173K)GFP failed
to change its localization in response to the expression
of constitutively activate RHO-1(G14V) (Fig. 5E,G).
Thus, RHO-1(G14V) regulates the localization of UNC-
13S in the dorsal nerve cord in a DAG-dependent man-
ner.
To confirm that the UNC-13SYFP-containing punc-
tate structures were sites of neurotransmitter release,
we carried out double-labeling experiments, using
SNB-1CFP expressed from a motor neuron-specific
promoter and UNC-13SYFP expressed from its own
pan-neural UNC-13S promoter. In the absence of RHO-
1(G14V) expression, UNC-13SYFP is diffusely local-
ized within the motor neurons with a few discreet
Figure 4. RHO-1 enhances acetylcholine release by DGK-1-
dependent and -independent mechanisms. Presynaptic expres-
sion (from the unc-17 promoter, N:C3 transferase or N:C3T) of
C3 transferase reduces the locomotion rate (A) and aldicarb sen-
sitivity (B) of dgk-1(sy428) mutant animals, although not to the
same level as animals with presynaptic expression of C3 trans-
ferase in nonmutant animals, indicating that some but not all
RHO-1 enhancement of ACh release occurs via inhibition of
DGK-1. Error bars indicate standard error of the mean. Statisti-
cal analysis was performed using a two-tailed t-test, and two
asterisks (**) indicates significance (p < 0.001).
Figure 3. RHO-1 enhancement of acetylcholine re-
lease is partially dependent on binding to DGK-1 and
binding of UNC-13 to DAG. (A) Body bends per
minute were counted for wild-type, N:RHO-1(G14V),
and N:RHO-1(G14VF25N) animals in wild-type, dgk-
1(sy428), and unc-13(s69);UNC13S(H173K)GFP
backgrounds. Presynaptic (unc-17 promoter) expres-
sion of the RHO-1(G14VF25N) mutant, which binds
DGK-1 poorly, increases locomotion, but not as
strongly as RHO-1(G14V). dgk-1(sy428) increased lo-
comotion of animals expressing the poor DGK-1-
binding RHO-1(G14VF25N) mutant but not RHO-
1(G14V). The non-DAG-binding UNC-13 (H173K)
mutant suppresses the locomotion of RHO-1(G14V)
animals to a level equivalent to that of RHO-
1(G14VF25N) animals. dgk-1(sy428) animals express-
ing RHO-1(G14VF25N) moved slightly slower com-
pared with RHO-1(G14V);dgk-1(sy428), although this
was not significant (p > 0.02). Error bars indicate stan-
dard error of the mean. Statistical analysis was per-
formed using a two-tailed t-test and significance is
indicated using one asterisk (*) 0.001 < p < 0.02, and
two asterisks (**) p < 0.001. (B) Presynaptic expres-
sion of RHO-1(G14V), and to a lesser extent the poor
DGK-1-binding RHO-1(G14VF25N), cause hypersen-
sitivity to aldicarb, suggesting that binding to DGK-1
is required for the full effect of RHO-1 on ACh re-
lease. In a dgk-1(sy428) mutant the weak DGK-1-
binding RHO-1(G14VF25N) shows the same hypersensitive response to aldicarb as the RHO-1(G14V) mutant. (C,D) Replacement of
endogenous UNC-13 with transgenic expression of a non-DAG-binding UNC-13S (H173K) mutant [unc-13(s69);nzIs25] partially
reduced the aldicarb sensitivity resulting from the expression of RHO-1(G14V) expressed from the unc-17 promoter [neuro:RHO-
1(G14V);U13(H173K)] (C), but not the aldicarb sensitivity resulting from unc-17-driven expression of the poor DGK-1-binding RHO-
1(G14VF25N) mutant [neuro:RHO-1(G14VF25N);U13(H173K)] (D). Error bars indicate standard error of the mean.
Rho enhances neurotransmitter release
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puncta that are colocalized with SNB-1CFP puncta
(data not shown). Upon heat-shock-induced expression
of RHO-1(G14V), the UNC-13SYFP became more
punctate and colocalized with the SNB-1CFP puncta
(Fig. 5F), although the UNC-13SYFP appeared to spread
beyond the sites defined by SNB-1CFP. Although the
number of UNC-13SYFP puncta was increased in ani-
mals expressing RHO-1(G14V), the number of SNB-
1CFP puncta was unaffected (Supplementary Fig. 2),
demonstrating that RHO-1(G14V) recruits UNC-13S to
pre-existing synapses. These results indicate that RHO-1
causes a spatially restricted increase in DAG levels at
sites of neurotransmitter release.
DAG-binding mutants of UNC-13 partially block
the RHO-1(G14V)-induced increase in
neurotransmitter release
In both C. elegans and mice hippocampal neurons,
stimulation of neurotransmitter release in response to
the DAG analog phorbol ester is substantially blocked by
the UNC-13 (H173K) mutation, which is unable to bind
DAG (Lackner et al. 1999; Rhee et al. 2002). Expression
of RHO-1(G14V) in animals possessing only the non-
DAG-binding UNC-13 H173K mutant results in a partial
block of RHO-1(G14V)’s effects, reducing both rates of
locomotion and sensitivity to aldicarb (Fig. 3A,C). How-
Figure 5. RHO-1(G14V) regulates the dis-
tribution of UNC-13SYFP in the dorsal
nerve cord. In A–E, digital images were con-
verted from gray scale into a 32-color look-
up table (NIH Image) to visualize pixel in-
tensities. (A–D) UNC-13SYFP (expressed
from the internal unc-13S promoter) was
primarily diffusely distributed in the dorsal
nerve cord axons of untreated (A) and heat-
shocked (B) wild-type animals, as well as
non-heat-shocked animals containing the
hsRHO-1(G14V) array (hsRHO-1*) (C).
(D) UNC-13SYFP became more punctate
in the dorsal cords of heat-shocked
hsRHO-1(G14V) (hsRHO-1*) animals.
(E) Unlike the wild-type protein, UNC-13S
(H173K)GFP, which is predicted not
to bind to DAG (Betz et al. 1998), remains
diffusely distributed in heat-shocked
hsRHO-1(G14V) (hsRHO-1*) animals.
(F) UNC-13S is localized to acetylcholine
release sites in heat-shocked hsRHO-
1(G14V) animals. Motor neuron nerve ter-
minals and UNC-13S were simultaneously
visualized in heat-shocked hsRHO-
1(G14V) animals with CFP-tagged synapto-
brevin (top) and YFP-tagged UNC-13S
(middle). (Bottom) In the merged image, it
is clear that most SNB-1CFP puncta are
colocalized with a UNC-13SYFP punc-
tum. The SNB-1CFP construct was spe-
cifically expressed in motor neurons (with
the acr-2 promoter). The UNC-13SYFP
construct was expressed throughout the
nervous system with the unc-13S pro-
moter. (G) Numbers of either UNC-
13SYFP or non-DAG-binding UNC-
13S(H173K)GFP puncta in dorsal nerve
cords were compared for animals carrying
the hs:RHO-1(G14V), or nontransgenic
(w.t.) animals plus or minus heat shock,
with the indicated UNC-13 marker. Digital
images were thresholded according to pixel
intensity, and puncta were counted manu-
ally. Bars are means ± SEM; numbers of
animals counted are given in brackets. Sig-
nificance was determined by a two-tailed
t-test. (*) Significantly differs from non-
heat-shocked hsRHO-1(G14V) (p < 0.02).
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ever, the constitutively active RHO-1(G14V) retains the
ability to strongly increase ACh release in UNC-
13(H173K) animals, suggesting that RHO-1 stimulates
release by both UNC-13-dependent and UNC-13-inde-
pendent mechanisms. The UNC-13(H173K) mutant has
very little effect on the aldicarb-induced paralysis of ani-
mals expressing the RHO-1(G14VF25N) mutant, which
binds DGK-1 poorly (Fig. 3A,D). These results suggest a
model in which RHO-1 acts presynaptically to increase
ACh release via two pathways—one depending on the
inhibition of DGK-1, which causes an increase in DAG
and relocalization of UNC-13 to release sites, and a sec-
ond that is independent of both DGK-1 and the ability of
UNC-13 to bind to DAG.
Acute regulation of RHO-1 increases muscle
sensitivity to acetylcholine
The heat-shock promoter we used to acutely express
constitutively active RHO-1(G14V) or C3 transferase
drives expression in more cell types than just neurons.
Thus, we investigated whether changes in RHO-1 signal-
ing could also affect muscle responsiveness to ACh. To
do this we tested for sensitivity to levamisole, an acti-
vator of the muscle nicotinic ACh receptors. We found
that heat-shock-driven expression of RHO-1(G14V)
caused animals to become hypersensitive to levamisole
(Fig. 6A), suggesting that RHO-1 may also increase syn-
aptic strength at a site distinct from the motor neurons.
Surprisingly, expression of C3 transferase from both the
heat-shock and unc-17 promoter caused a slight increase
in muscle sensitivity to levamisole (Fig. 6B,C). Presyn-
aptic expression of either the constitutively active RHO-
1(G14V) or the poor DGK-1-binding RHO-1(G14VF25N)
from the unc-17 promoter caused no change in the re-
sponse to levamisole (Fig. 6C).
Discussion
We show that inhibition of endogenous RHO-1 activity
with C3 transferase causes a dramatic switch in animal
behavior toward slow locomotion and decreased ampli-
tude of body bends, suggesting that signaling through
RHO-1 is required for wild-type levels of locomotion.
Coincident with these behavioral changes, C3 transfer-
ase decreases release of ACh when expressed either
acutely in various cell types, including motor neurons
and muscles (heat-shock expression in adults), or in
ACh-releasing neurons (from the unc-17 promoter).
Transgenic expression of a constitutively active RHO-
1(G14V) mutant has the opposite effect: Animals move
more quickly and with exaggerated body bends. Markers
for both gross motor neuron morphology and for ACh
release sites reveal no changes in response to increased
RHO-1 signaling. Thus, RHO-1 acts presynaptically at
pre-existing synapses to stimulate neurotransmitter re-
lease at the C. elegans neuromuscular junction and
thereby modulates locomotion.
The hyperactive locomotion behavior and increased
aldicarb sensitivity of RHO-1(G14V)-expressing animals
is very similar to that of both wild-type animals exposed
to the DAG analog phorbol ester and animals with loss-
of-function mutations in goa-1 or dgk-1 (Mendel et al.
1995; Segalat et al. 1995; Hajdu-Cronin et al. 1999; Lack-
ner et al. 1999; Miller et al. 1999; Nurrish et al. 1999). In
the case of goa-1 mutants, hyperactive locomotion is
caused by an increase in both DAG and the DAG-bind-
ing UNC-13 protein at ACh release sites (Nurrish et al.
1999). Acute expression of RHO-1(G14V) also promotes
DAG-dependent accumulation of UNC-13 at sites of
ACh release in dorsal motor neurons. UNC-13 is a core
component of the synaptic release machinery essential
for the priming of synaptic vesicle exocytosis (Richmond
Figure 6. Acute expression of RHO-1(G14V) increases
muscle response to acetylcholine (ACh). Muscle re-
sponse to ACh was measured by determining the onset
of paralysis induced by the nicotinic agonist levamisole
at 100 µM. (A) Heat-shock expression of a constitu-
tively active RHO-1(G14V) mutant [hs:RHO-
1(G14V) + heat shock] resulted in a faster onset of pa-
ralysis in the presence of levamisole compared with
non-heat-shocked [hs:RHO-1(G14V) − heat shock] and
nontransgenic controls (wt − heat shock and wt + heat
shock). (B) Heat-shock expression of the RhoA inhibitor
C3 transferase (hs:C3T + heat shock) caused a very
slight increase in onset of paralysis in response to le-
vamisole compared with non-heat-shocked (hs:C3T −
heat shock) and nontransgenic controls (wt−heat shock
and wt + heat shock). (C) Animals with presynaptic
(p.unc-17) expression of RHO-1(G14V) [neuro:RHO-
1(G14V)] or RHO-1(G14VF25N) [neuro:RHO-
1(G14VF25N)] paralyzed at the same rate as nontrans-
genic (wt) animals when exposed to levamisole. Presyn-
aptic expression of C3 transferase from the unc-17
promoter (neuro:C3T) causes a slight hypersensitivity
of the muscles to ACh, as shown by a slight increase in
response to levamisole. Error bars indicate standard er-
ror of the mean.
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et al. 1999, 2001). Thus, we are able to show that RHO-1
signaling modulates a core component of the synaptic
release machinery.
How does RHO-1(G14V) increase DAG at release
sites? DGK-1 and DGK are DAG kinases, a family of
lipid kinases that phosphorylate the membrane-bound
second messenger DAG to phosphatidic acid (for re-
views, see van Blitterswijk and Houssa 2000; Luo et al.
2004). As noted above, animals expressing constitutively
active RHO-1(G14V) have a similar phenotype to dgk-1
mutants, and dgk-1 mutants do not increase the locomo-
tion of animals expressing RHO-1(G14V) in the motor
neurons, suggesting they act in the same pathway. Hu-
man RhoA has been shown to inhibit DGK in vitro,
suggesting a role for RhoA in regulating DAG levels
(Houssa et al. 1999), and now we show that C. elegans
RHO-1 is able to bind to DGK-1. Furthermore, a RHO-1
mutant with a reduced ability to bind DGK-1, RHO-
1(G14VF25N), has a reduced ability to stimulate ACh
release. Our results are most consistent with a signal
transduction cascade leading from activation of RHO-1,
through an increase in DAG, via inhibition of DGK-1, to
the recruitment of UNC-13 to sites of ACh release. We
and others (Hajdu-Cronin et al. 1999; Lackner et al. 1999;
Miller et al. 1999; Nurrish et al. 1999) have also shown
that two antagonistic G-protein signaling pathways con-
trol DAG levels in C. elegans motor neurons. Thus, we
can place this novel RHO-1 signaling pathway within a
larger model of how DAG levels, and thus neurotrans-
mitter release, are regulated within C. elegans motor
neurons (Fig. 7).
In dgk-1-null mutants, UNC-13 relocates to the motor
neuron plasma membrane, rather than to specific release
sites (Nurrish et al. 1999). In contrast, RHO-1(G14V)
causes DAG levels to increase only at release sites, as
shown by the specific localization of DAG-binding
UNC-13 (although the UNC-13 does spread further than
the SNB-1 release-site marker). This localized increase in
DAG suggests that activation of RHO-1 does not cause a
generalized inhibition of DGK-1, but rather a specific
inhibition of DGK-1 at sites of neurotransmitter release,
thus ensuring that DAG levels increase only at sites of
ACh release.
Two lines of evidence indicate that RHO-1 can en-
hance ACh release independently of DGK-1 inhibition.
First, inhibition of endogenous RHO-1 by C3 transferase
still reduces locomotion and ACh release in a dgk-1-null
mutant, inconsistent with a model in which RHO-1 sig-
nals exclusively by inhibiting DGK-1. Second, the non-
DAG-binding UNC-13(H173K) mutant only partially
blocks signaling from the constitutively active RHO-
1(G14V). The UNC-13(H173K) mutant almost com-
pletely blocks the ability of low concentrations of the
DAG analog PMA to stimulate release, demonstrating
that UNC-13 is the primary high-affinity target of DAG
effects on ACh release (Lackner et al. 1999). These re-
sults suggest that RHO-1 can stimulate ACh release by a
second, DGK-1-and DAG-independent, pathway. Ac-
cording to this model, we would predict that expression
of RHO-1(G14V), which activates both pathways, would
further increase ACh release and locomotion rates in
dgk-1 mutants, which mimics activation of only one of
the RHO-1 pathways. However, we did not observe any
such increase; possibly the locomotion rates of dgk-1
animals may represent the maximum rate in our assay
that cannot be increased, even by activation of the DGK-
1-independent pathway.
Interestingly, ACh release stimulated by expression of
the RHO-1(G14VF25N) mutant, which binds to DGK-1
poorly, is not inhibited by the UNC-13(H173K) mutant.
Perhaps RHO-1(G14VF25N) fails to inhibit DGK-1 and
stimulates ACh release entirely by the DGK-1-indepen-
dent pathway. Accordingly, null mutations in dgk-1 en-
hance both the rate of locomotion and aldicarb sensitiv-
ity of animals expressing the poor DGK-1-binding RHO-
1(G14VF25N) to equivalent levels of the strong DGK-1-
binding RHO-1(G14V). It appears that RhoA constructs
containing the F25N mutation are quite common, and
indeed we were unable to locate a source of RhoA with-
out this mutation. The F25 residue is immediately N-
terminal to the Rho switch 1 region and makes contacts
with the Rho-binding domain in a RhoA-PKN crystal
structure (Maesaki et al. 1999). It is possible that effects
of RhoA on DAG signaling have been previously missed
due to the use of the RhoA(F25N) mutant.
What is the DGK-1-independent pathway by which
RHO-1 stimulates release presynaptically? One possibil-
ity is that RHO-1 reorganizes presynaptic actin (Hall
1998; Dillon and Goda 2005). Changes in the actin cyto-
Figure 7. RHO-1 acts via three distinct pathways to increase
synaptic strength at the C. elegans neuromuscular junction. We
propose an addition to the competing G-protein pathway model
in C. elegans motor neurons (Lackner et al. 1999; Miller et al.
1999; Nurrish et al. 1999). To this pathway we added RHO-1 as
a negative regulator of DGK-1. Activation of RHO-1 causes a
loss of DGK-1 activity, leading to a stabilization of diacylglyc-
erol (DAG) levels at sites of release. Presynaptic DAG recruits
UNC-13 to release sites, and the accumulation of UNC-13 at
release sites correlates with increases in ACh release. We fur-
ther propose that RHO-1 acts by a second presynaptic pathway
that is independent of DGK-1 inhibition and of DAG-binding to
UNC-13. Finally, our data suggest that RHO-1 expression at a
site other than the motor neuron potentiates the response of the
muscle to ACh.
McMullan et al.
72 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on August 24, 2015 - Published by genesdev.cshlp.orgDownloaded from 
skeleton are a prerequisite for exocytosis, enabling dock-
ing and fusion of secretory vesicles with the plasma
membrane (for review, see Dillon and Goda 2005). In
neurons, changes in presynaptic actin modulate vesicle
fusion at active zones (Morales et al. 2000), increase the
movement of actin-tethered synaptic vesicles from the
reserve pool to active zones (Mochida et al. 1994; Kuromi
and Kidokoro 1998; Hilfiker et al. 2005), and promote
endocytosis of synaptic vesicles following neurotrans-
mitter release (Shupliakov et al. 2002). Alternatively, the
DGK-1-independent RHO-1 pathway could involve the
aggregation of synaptic proteins to existing synapses
(Wang et al. 2005). Constitutively active RHO-1(G14V)
does not generate new aggregations of synaptobrevin
(SNB-1)-labeled synaptic vesicles, ruling out the forma-
tion of new functional synapses. However, we were un-
able to measure numbers of SNB-1 agregations in C3
transferase-expressing animals, so it is possible that re-
ducing RHO-1 activity could cause the removal of re-
lease sites. A genetic screen in C. elegans for suppressors
of the increased ACh release phenotype of neuronally
expressed RHO-1(G14V) (E. Hiley and S.J. Nurrish, un-
publ.) has identified a number of recessive mutants; the
characterization of these mutants should shed light on
the DGK-1-independent RHO-1 signaling pathway.
A third mechanism by which RHO-1 enhances synap-
tic strength is revealed by the finding that expression of
RHO-1(G14V) from the widely expressed heat-shock pro-
moter causes hypersensitivity of the muscles to ACh.
The simplest explanation for this finding is that the con-
stitutively active RHO-1(G14V) acts post-synaptically to
increase muscle responsiveness to ACh. Rho is known to
increase the contraction by actin–myosin filaments via
Rho-associated kinase, which phosphorylates myosin
light chain (Kimura et al. 1996). Alternatively, RHO-1
stimulation could increase clustering (Weston et al.
2003) or activity of the nicotinic ACh receptors by an as
yet unidentified mechanism. Unexpectedly, we find that
heat-shock and neuronal expression of C3 transferase
also causes muscles to become slightly hypersensitive to
ACh. The decreased release of ACh triggered by the C3
transferase-dependent inhibition of RHO-1 may induce
homeostatic compensation in the muscles. A similar
compensation effect has been observed at the Drosophila
neuromuscular junction (Davis and Goodman 1998).
All of the components in our proposed DGK-1-depen-
dent Rho signaling pathway are conserved in mammals,
including RHO-1(RhoA), DGK-1(DGK), and UNC-13
(munc13-1). Since RhoA, DGK, and munc13-1 are pres-
ent in the mammalian brain, it is possible that RhoA
regulates neurotransmitter release in mammals by
modulating DAG levels. If so, DAG kinases and their
regulators might be good targets for drugs to alter syn-
aptic signaling in the brain.
Materials and methods
Strains
The N2 (wild-type) strain was obtained from the Caenorhabdi-
tis Genetics Center (University of Minnesota). The dgk-
1(sy428) (a gift of P. Sternberg, California Institute of Technol-
ogy, Los Angeles, CA) is an early nonsense mutation that pro-
duces no detectable DGK-1 protein (Jose and Koelle 2005), and
thus likely represents a null mutant. For locomotion and aldi-
carb assays, UNC-13 constructs were expressed in unc-13(s69)
mutants. All strains were cultivated at 20°C unless otherwise
stated and were maintained as described previously (Brenner
1974).
Transgenes and germline transformation
Plasmids (listed as QT#, SJN, or RJM) were constructed by stan-
dard techniques, and sequences were verified by sequencing.
Transgenic strains (listed as QT) were isolated by microinjec-
tion of 100 ng/µL of plasmid, unless otherwise described below,
together with ttx-3gfp at 100 ng/µL (a gift of O. Hobert, Co-
lumbia University, New York, NY) or unc-122gfp at 50 ng/µL
(a gift of P. Sengupta, Brandeis University, Waltham, MA) as a
marker. Unless otherwise stated, all injections were performed
into N2 animals. Plasmids and transgenic strains were con-
structed as follows.
RHO-1 transgenes cDNA for RHO-1 was isolated from whole
C. elegans RNA using the SMART RACE kit (Clontech) as per
the manufacturer’s instructions. The sequence was modified by
PCR to create the G14V mutation and subcloned either into the
pPD79.48 (a gift of A. Fire, Stanford University, Stanford, CA)
heat-shock vector (QT#42) or a vector driving expression from
the unc-17 cholinergic-specific promoter (a 3213-base-pair [bp]
fragment located −1226 to −4439 bp 5 of the unc-17 start codon,
a gift of J. Kaplan, Massachusetts General Hospital, Boston, MA)
(QT#220). These plasmids were injected at 5 ng/µL. nzIs1 and
nzIs28 contain an integrated version of the QT#42 and QT#220
plasmids, respectively. Plasmids SJN349 and SJN327 are iden-
tical to QT#42 and QT#220, respectively, except they contain a
point mutation resulting in the rho-1 amino acid change F25N.
Stable arrays of SJN349 (nzEx99) and SJN327 (nzEx72) were gen-
erated by injection into wild-type animals. Transgenes express-
ing RHO-1 N-terminally tagged with GFP, MYC, or HA lost
their ability to stimulate ACh release and locomotion.
C3 transferase transgenes The C3 transferase coding sequence
was a gift of R. Treisman (Cancer Research UK, London, UK).
C3 transferase was N-terminally tagged with GFP (derived from
pPD95.75, a gift from A. Fire) and expressed from a heat-shock
promoter (QT#99) or from the unc-17 promoter (SJN266). These
transgenes were injected at 1 ng/µL. nzEx4 and nzEx95 contain
extrachromosomal versions of QT(99 and SJN266, respectively.
UNC-13 transgenes For UNC-13 and SNB-1 visualization:
nuIs59 contains rol-6, KP#291 (which encodes a full-length unc-
13SYFP fusion gene that restores locomotion to animals car-
rying unc-13 alleles) and KP#282 (which encodes a SNB-1CFP
fusion expressed from the acr-2 promoter [a gift of Y. Jin, Uni-
versity of California at Santa Cruz, Santa Cruz, CA], which is
expressed in the neurons VA, DA, VB, DB, IL1, RMD, and PVQ)
integrated in a wild-type background. KP#273 encodes UNC-
13SGFP, which contains a point mutation resulting in the
amino acid change H173K. nzIs25 contains an integrated ver-
sion of KP#273 in an unc-13 (s69) background. Strain QT262 has
both the nzIs1[hsrho-1(G14V)] and nuIs59 integrants. Strain
QT426 has both the nuIs59 and nzIs28[Nrho-1(G14V)] inte-
grants. Strain QT336 has the nzIs1 and nzIs25 integrated arrays
in the unc-13(s69) background. As rol-6 expression interferes
with locomotion and aldicarb assays, we used nuIs46, which is
an integration of the KP#268 (UNC-13SGFP) plasmid instead
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of nuIs59. Strain QT148 has both the nzIs1 and nuIs46 inte-
grants in the unc-13(s69) background. Strain QT328 has the
nzIs25 and nzIs28 integrated arrays in an unc-13(s69) back-
ground. nzEx122 has SJN327 [p.unc-17RHO-1(G14VF25N)],
KP#291, and KP#282 as a stable array in unc-13(s69) animals.
Induction of heat-shock-inducible transgenes
In all cases, expression from the heat-shock promoter was
achieved using two rounds of heat shock for 60 min at 30°C,
separated by 30 min at 20°C, followed by recovery for 30 min at
20°C.
Microscopy
Strains expressing punc-47:GFP, punc13s:UNC13SYFP, pacr-
2:SNB-1CFP, or punc-13s:UNC13S(H173K)GFP were im-
aged by mounting on agarose pads and viewed on a Bio-Rad 2100
upright multiphoton confocal microscope with a Nikon 60×
objective. Images were obtained using LaserSharp software
(Bio-Rad). Digital images were processed to give maximum
intensity projections of a z-series using ImageJ (NIH). Images
were blinded with respect to genotype and treatment, and
UNC-13SYFP and SNB-1CFP puncta were counted manu-
ally. The following strains were used for microscopy: EG1285
[oxIs12], QT195 [nzIs1;oxIs12], QT316 [nzIs28;oxIs12], QT427
[nzEx95;oxIs12], KP1683 [nuIs59], QT262 [nzIs1;nuIs59],
QT181 [nzIs25], QT336 [nzIs1;nzIs25], QT426 [nzIs28;nuIs59].
Analysis of locomotion and sensitivity to drug treatment
Sensitivity to 1 mM aldicarb (Greyhound Chromatography) or
100 µM levamisole (Sigma) on NGM plates with food was de-
termined by analyzing the onset of paralysis as described previ-
ously (Nurrish et al. 1999). For each experiment, 25 animals
were tested, and each experiment was repeated at least five
times. For locomotion rates, the number of body bends per
minute was counted by visual inspection, and animals were
assayed on NGM plates in the presence of food. Each animal
was assayed three times for 1 min each. At least five animals
were tested in all cases.
Plasmids for mammalian expression and recombinant
protein purification
pcDNA1DGKVSV was kindly provided by W.J. van Blitter-
swijk (Nederlands Kanker Instituut, Amsterdam, Netherlands).
pcDNA3.1DGK-accVSV containing residues 731–942 and in-
cluding the accessory domain of DGK was generated by PCR.
Plasmids for the expression of mammalian RhoA in the pRK5
vector were a gift from A. Hall (MRC Laboratory for Molecular
Cell Biology, London, UK). These plasmids contained a phenyl-
alanine to aspartate mutation at position 25 that was corrected
by PCR (QT#240). pEFC3 for expression of C3 in mammalian
cells and pGexKG-PKN(1–511), pGexKG-mDia(47–257), and
pGexKG-ROCKII(348–1018) for purification of recombinant
proteins were gifts from R. Treisman. C. elegans rho-1 was am-
plified from C. elegans cDNA using the SMART RACE cDNA
kit (Clontech). The rho-1 cDNA was cloned into pRK5 and N-
terminally tagged with the MYC epitope (SJN361). This was
further mutated by PCR to give the amino acid changes G14V
(SJN307) and G14VF25N (SJN342). The dgk-1 cDNA (Nurrish et
al. 1999) was cloned into the pCDNA3.1 mammalian expres-
sion vector and C-terminally tagged with the HA epitope
(RJM001). The dgk-1 accessory domain, residues 703–950, was
cloned into pCNA3.1 and C-terminally tagged with HA
(SJN345).
Cell culture and transfection
Cos7 cells were grown at 37°C in Dulbecco’s modified Eagles
medium supplemented with 10% fetal calf serum and antibiot-
ics. Cell transfections were performed using Genejuice (Nova-
gen) according to the manufacturer’s instructions. In all cases,
between 2 and 5 µg of DNA was transfected, and cells were used
for experiments 48 h after transfection.
Immunoprecipitation and Western blotting
Following transfection, cells were scrape lysed in 150 mM
NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 1% Nonidet
P-40, and protease inhibitors. Immunoprecipitations were car-
ried out with ∼200 µg of cell lysate and 2 µg of antibody using
standard methods. Washes were performed in 150 mM NaCl, 50
mM Tris-HCl (pH 8.0), 5 mM MgCl2, 1% Nonidet P-40, and
protease inhibitors. Immunoprecipitated proteins were sub-
jected to SDS–polyacrylamide gel electrophoresis and immuno-
blotting, together with 20 µg of total lysates, using standard
methods. The following antibodies were used for immunopre-
cipitation and immunoblotting: anti-myc tag 9E10 (Santa Cruz),
anti-VSV tag (Abcam), anti-tubulin E7 (Developmental Studies
Hybridoma Bank, University of Iowa), and anti-HA (Santa
Cruz). Densitometric analysis was performed using Quantity
One software (Bio-Rad). We attempted to measure the DAG
kinase activity of DGK-1 bound to RHO-1; however, levels of
coimmunopreciptated DGK-1 were too low for results from the
DAG kinase assay (Nurrish et al. 1999; Jose and Koelle 2005) to
be reliable.
GST pulldowns
GST pulldowns using recombinant GST-PKN(1–511), GST-
mDia(47–257), and GSTROCKII(348–1018) were performed as
described (Sahai et al. 1998) with the following modifications.
pcDNA3.1mycV14RhoA and pcDNA3.1mycV14N25RhoA
were transfected into Cos7 cells as described above. Forty-eight
hours after transfection, cells were lysed in 150 mM NaCl, 50
mM Tris-HCl (pH 8.0), 5 mM MgCl2, 1% Nonidet P-40, and
protease inhibitors. Two-hundred micrograms of cell lysate was
incubated with 20 µg of GST fusion protein for 2 h at 4°C, and
washes were performed. Following SDS–polyacrylamide gel
electrophoresis and immunoblotting, bands were detected using
a FluorSmax fluorimeter, and densitometric analysis was car-
ried out using Quantity One software (Bio-Rad). Values repre-
sent the means of three separate experiments.
Statistical analysis
In all cases statistical analysis was performed using an unpaired
two-tailed t-test. P values between 0.02 and 0.001 (significant)
are indicated on figures using one asterisk, and P values of 0.001
or less (highly significant) are indicated with two asterisks.
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